PAXMAN receives market approval in Mexico and plans Q2 launch with license partner Teva Pharmaceutical Industries Ltd
PAXMAN announces that the company has received market approval in Mexico for its market leading scalp cooling system which reduces hair loss during chemotherapy treatment. PAXMAN and license partner Teva will now increase their activities in preparation for an official launch later in the second quarter.The market approval in Mexico is equivalent to the company's FDA clearance in the USA. It thus gives the right to market and sell the scalp cooling system for use in connection with chemotherapy treatment of cancer. “I am excited that we have received market approval in Mexico even